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Abstract
Background: Depression and non-communicable diseases (NCDs) account for a growing burden on health systems
in low- and middle-income countries (LMICs). Depression is generally associated with the outcomes of NCDs and is
an important barrier to consistent NCD care management. There is great need to understand the efficacy of
interventions to treat depression for people with NCDs, but there is a paucity of evidence of the efficacy of the
interventions in LMICs. Therefore, the broad objective of this review is to systematically review the literature on the
effectiveness of depression management among patients with diabetes and hypertension to improve outcomes.
Methods: This is a systematic review to assess the evidence of the effect of depression management in diabetic
and hypertensive patients on diabetes and hypertension outcomes in LMICs. Two independent reviewers will
search articles on PubMed, EMBASE, PsycINFO, and Global Index Medicus. Two reviewers will then screen the
articles independently based on predefined criteria. We will use standard methods as recommended by the
Cochrane Collaboration of assessing quality of evidence and publish our report using the PRISMA guidelines.
Discussion: The findings from this review will provide evidence to be used in guiding practice and policy on how
to integrate depression management in diabetes and hypertension clinics.
Systematic review registration: PROSPERO CRD42017068257
Keywords: Depression, Non-communicable diseases, Diabetes, Hypertension, Outcomes, Low- and middle-income
countries, Systematic review, Protocol
Background
Non-communicable diseases (NCDs) are a growing bur-
den on the health systems in low- and middle-income
countries (LMICs) [1, 2]. Studies show that the comor-
bidity of depression and chronic diseases such as dia-
betes is common in LMICs and they are significant
causes of morbidity, disability, and mortality [3, 4]. De-
pression is a mood disorder characterized by changes in
ones feelings (e.g., feels sad or empty), physical status
(e.g., loss of energy), thought process (e.g., diminished
ability to think or concentrate, or more indecisiveness),
and behavior (e.g., thoughts of death or suicide) [5]. De-
pression is estimated to affect 350 million people world-
wide [6, 7]. The prevalence of comorbidity of physical
NCDs, such as diabetes and hypertension, and depres-
sion is increasing. The 12-month prevalence of comor-
bid depression with NCDs worldwide is between 9.3%
and 23.0% of people [8, 9]. Depression affects one in
three people with hypertension [6] while one in four pa-
tients with diabetes have depression [10, 11]. Modifiable
risk factors for NCDs are exacerbated by poor mental
health, and on the other hand, NCDs are a risk factor
for depression [12]. Evidence indicates a bidirectional re-
lationship between depression and individual chronic
diseases [10]; for instance, depression increases the risk
of the development of type 2 diabetes and subsequent
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risks of hyperglycemia [11]. Furthermore, a diagnosis of
type 2 diabetes increases the risk of depression and can
contribute to a more severe course of depression [11].
Some studies have found non-adherence to prescribed
medication among cardiovascular diseases (CVD)
patients with depressive symptoms [13, 14].
Non-adherence to medication has been suggested to be
a contributor to the increased morbidity and mortality
seen in CVD and comorbid mental disorders [15]. Many
studies that examined the prevalence of depression
among patients with diabetes mellitus and hypertension
recommend including routine screening of depression in
patients with diabetes or hypertension and referral for
appropriate management [16–19].
A systematic review by Mendenhall et al. showed that
one in three people with diabetes in LMICs has
co-morbid depression which is suggested to be higher
than in higher income countries [2]. As such, the review
concluded that there is need for integrating mental
health care into diabetes care within LMIC health sys-
tems. Furthermore, the review recommended the need
for research around the cost of oversight of mental
health problems among people with chronic illness in
LMICs [2]. The review highlighted that treating depres-
sion among people with diabetes is cost-effective in
high-income countries (HICs) [2]. The observation made
in the Mendenhall review confirms findings of another
systematic review of comorbid depression and diabetes
in the USA (by Atlantis et al.) which suggested that col-
laborative care for depression significantly improves
both depression and glycaemia outcomes [20]. The sys-
tematic reviews from HICs indicate that collaborative
care is more effective than usual care for improving de-
pression outcomes in people with comorbid diabetes
[20–22]; however, there is paucity of data on the effect
of treating depression among patients with diabetes and
hypertension in LMICs. The National Institute for
Health and Care Excellence (NICE) guidelines for de-
pression in adults with a chronic physical health prob-
lem, such as diabetes and hypertension, recommend
collaborative care [23]. Accordingly, there is great need
to understand the efficacy of interventions to treat de-
pression for people with chronic disease since the Men-
denhall review did not address the efficacy of
interventions. The Atlantis review looked at intervention
efficacy but did not identify LMIC studies for inclusion.
Therefore, our systematic review will assess the evidence
of the effect of management of depression in diabetic
and hypertensive patients on diabetes and hypertension
outcomes in LMICs. Our review also aims to identify ef-
ficacy LMIC studies that may have been missed by previ-
ous studies by searching the Global Health database and
using search terms to identify LMIC studies. The sys-
tematic review will inform practice and policy on the
need to integrate depression management in the man-
agement of patients with diabetes and hypertension.
Methods
Our objective is to identify studies examining the effect
of depression management on diabetes and hypertension
outcomes. We will use the Cochrane Collaboration
Handbook [24] as the systematic review guide in con-
ducting the systematic review. We will utilize the Pre-
ferred Reporting Items of Systematic Reviews and
Meta-Analyses Protocol (PRISMA) [25, 26] guidelines in
reporting the review. The protocol has been registered
on the PROSPERO database (Ref: CRD42017068257)
and will follow the Preferred Reporting Items of System-
atic Reviews and Meta-Analyses Protocol (PRISMA-P)
guidelines [27].
Data sources and searches
We will search four databases from 1990 to present:
PubMed, EMBASE, PsycINFO, and Global Index Medi-
cus. We will include all studies from 1990 because we
anticipated that adequate number of studies would have
been published thereafter to meaningfully examine the
effectiveness of depression management on NCDs in
LMICs. The search strategy will include the search con-
cepts (1) depression, (2) interventions for depression
management, (3) diabetes or glycemic control or hyper-
tension or blood pressure control, and (4) LMICs. Ap-
propriate controlled vocabulary words will be tailored to
each database. Some of the search terms are based on
existing reviews [2, 6, 20, 28]. We have developed an
electronic search strategy of combined search terms for
one database as shown in Table 1. We will also search
reference lists of all studies that will meet our inclusion
criteria and relevant systematic reviews for additional
potentially eligible primary studies. Authors of included
reviews will be contacted to clarify reported published
information and to seek unpublished results. We will
perform a forward citation search to identify additional
studies. Appendices for all strategies used, including a
list of sources screened and relevant reviews or primary
studies reviewed, will be provided. We will exclude
non-English articles during the full-text screening stage
as resources are not available to translate the data. Any
potentially relevant non-English articles will be listed in
review to indicate further available evidence.
Eligibility criteria
Any studies that examined the outcomes of an interven-
tion for depression management on diabetes or hyper-
tension outcomes (HbA1c, fasting blood glucose,
depression scores, and blood pressure (BP) measure-
ments) for patients with diabetes mellitus or hyperten-
sion will be eligible for inclusion. The minimum and
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maximum time periods for follow-up of diabetes and
hypertension health outcomes will be 3 and 12months
respectively.
Depression is a mood disorder characterized by
changes in ones feelings (e.g., feels sad or empty), phys-
ical status (e.g., loss of energy), thought process (e.g., di-
minished ability to think or concentrate, or more
indecisiveness), and behavior (e.g., thoughts of death or
suicide) [5].
Hypertension is defined as systolic BP level of ≥ 140
mmHg and diastolic BP of ≥ 90mmHg [29]. The diag-
nostic of hypertension is made when the average of two
or more diastolic BP measurements on at least two sub-
sequent visits is ≥ 90 mmHg or when the average of mul-
tiple systolic BP readings on two or more subsequent
visits is consistently ≥ 140 mmHg.
Diabetes is defined as a group of metabolic diseases
characterized by hyperglycemia resulting from defects in
insulin secretion, insulin action, or both [30]. The cri-
teria for diagnosis of diabetes include a fasting plasma
glucose (FPG) level > 126 mg/dl (7.0 mmol/l) or a casual
plasma glucose > 200 mg/dl (11.1 mmol/l) or HbA1C
test with a threshold of ≥ 6.5% meets the threshold for
the diagnosis of diabetes [30]. We will only include type
2 diabetes in our review; thus, type 1 diabetes and gesta-
tional diabetes will be excluded.
The following PICOS describes the review inclusion
criteria and search strategy concepts:
Population: Adults (18 years or older) suffering from
diabetes or hypertension or both conditions.
Intervention: Depression management interventions
including screening strategy for depression, psycho-
logical intervention, or medication management.
Comparator: No routine screening or diagnosis for de-
pression in patients with diabetes or hypertension.
Outcome: Diagnosis of depression; HBA1c, fasting
blood glucose, blood pressure control, and depression
scores.
Study design: Randomized control trials and
quasi-experimental and observational studies will be eli-
gible for inclusion because of paucity of data from
LMICs.
Setting: Primary and secondary health care service de-
livery in LMIC. We only include studies conducted in
the low-income countries and the lower-middle income
countries as defined by the World Bank [31].
We will exclude studies involving patients less than 18
years old and those with additional co-occurring medical
conditions.
Study selection
We will download all titles and abstracts retrieved by
electronic searching to Endnote and remove duplicates.
Two reviewers [MU and MN] will independently screen
the titles and abstracts for inclusion. We will retrieve the
full-text study reports/publication, and two reviewers
[MU and MN] will independently screen the full text
and identify studies for inclusion and identify and record
reasons for exclusion of the ineligible studies. We will
resolve any disagreement through discussion or, if
Table 1 Search strategy
Database Search terms
PubMed ((((africa[MeSH Terms]) OR (((Africa[Title/Abstract] OR Asia[Title/Abstract] OR “low-income country”[Title/Abstract] OR “low-income
countries”[Title/Abstract] OR “low” [Title/Abstract] AND “middle-income countries”[Title/Abstract] OR “middle-income country”[Title/
Abstract] OR “middle income countries”[Title/Abstract] OR “Sub-Saharan Africa”[Title/Abstract] OR Afghanistan[Title/Abstract] OR Benin[Title/
Abstract] OR “Burkina Faso”[Title/Abstract] OR Burundi[Title/Abstract] OR “Central African Republic”[Title/Abstract] OR Chad[Title/Abstract]
OR Comoros[Title/Abstract] OR Congo[Title/Abstract] OR Eritrea[Title/Abstract] OR Ethiopia[Title/Abstract] OR Gambia[Title/Abstract] OR
guinea[Title/Abstract] OR “Guinea-Bissau”[Title/Abstract] OR Haiti[Title/Abstract] OR “North Korea”[Title/Abstract] OR “Democratic People’s
Republic of Korea”[Title/Abstract] OR Liberia[Title/Abstract] OR Madagascar[Title/Abstract] OR Malawi[Title/Abstract] OR Mali[Title/Abstract]
OR Mozambique[Title/Abstract] OR Nepal[Title/Abstract] OR Niger[Title/Abstract] OR Rwanda[Title/Abstract] OR Senegal[Title/Abstract] OR
“Sierra Leone”[Title/Abstract] OR Somalia[Title/Abstract] OR “South Sudan”[Title/Abstract] OR Tanzania[Title/Abstract] OR Togo[Title/Abstract]
OR Uganda[Title/Abstract] OR Zimbabwe [Title/Abstract] OR Armenia[Title/Abstract] OR Bangladesh[Title/Abstract] OR Bhutan[Title/
Abstract] OR Bolivia[Title/Abstract] OR “Cabo Verde”[Title/Abstract] OR “Cape Verde”[Title/Abstract] OR Cambodia[Title/Abstract] OR
Cameroon[Title/Abstract] OR Congo[Title/Abstract] OR “Cote D’Ivoire”[Title/Abstract] OR Djibouti[Title/Abstract] OR Egypt[Title/Abstract] OR
“el Salvador”[Title/Abstract] OR Ghana[Title/Abstract] OR Guatemala[Title/Abstract] OR Honduras[Title/Abstract] OR India[Title/Abstract] OR
Indonesia[Title/Abstract] OR Kenya[Title/Abstract] OR Kiribati[Title/Abstract] OR Kosovo[Title/Abstract] OR Kyrgyz[Title/Abstract] OR
Kyrgyzstan[Title/Abstract] OR Lao[Title/Abstract] OR Laos[Title/Abstract] OR Lesotho[Title/Abstract] OR Mauritania[Title/Abstract] OR
Micronesia[Title/Abstract] OR Moldova[Title/Abstract] OR Mongolia[Title/Abstract] OR Morocco[Title/Abstract] OR Myanmar[Title/Abstract]
OR Nicaragua[Title/Abstract] OR Nigeria[Title/Abstract] OR Pakistan[Title/Abstract] OR “Papua New Guinea”[Title/Abstract] OR
Philippines[Title/Abstract] OR Samoa “Sao Tome”[Title/Abstract] OR Principe[Title/Abstract] OR “Solomon Islands”[Title/Abstract] OR “Sri
Lanka”[Title/Abstract] OR Sudan[Title/Abstract] OR Swaziland[Title/Abstract] OR Syria[Title/Abstract] OR “Syrian Arab Republic”[Title/Abstract]
OR Tajikistan[Title/Abstract] OR Timor[Title/Abstract] OR Tonga[Title/Abstract] OR Tunisia[Title/Abstract] OR Ukraine[Title/Abstract] OR
Uzbekistan[Title/Abstract] OR Vanuatu[Title/Abstract] OR Vietnam[Title/Abstract] OR “West Bank”[Title/Abstract] OR Gaza[Title/Abstract] OR
Yemen[Title/Abstract] OR Zambia [Title/Abstract] OR “developing countries”[MeSH Terms]))) AND (((diabetes[Title/Abstract] OR
diabetic[Title/Abstract] OR hypertension[Title/Abstract] OR “blood pressure”[Title/Abstract] OR hypertensive[Title/Abstract])) OR
“hypertension”[MeSH Terms] OR “diabetes mellitus”[MeSH Terms])) AND (((depression[Title/Abstract] OR depressed[Title/Abstract] OR
depressive[Title/Abstract])) OR “depressive disorder” [MeSH Terms]) OR depression[MeSH Terms] AND (“screening” [Title/Abstract] OR “Mass
Screening” [MeSH Terms]) AND (“CBT” [Title/Abstract] OR “Antidepressant Medication” [Title/Abstract] OR “Psychological Intervention” [Title/
Abstract])
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required, we will consult a third reviewer [MM] for con-
sensus agreement. We will list studies that initially ap-
peared to meet the inclusion criteria but that we later
excluded. We will collate multiple reports of the same
study so that each study rather than each report is the
unit of interest in the review. We will also provide any
information we can obtain about ongoing studies. We
will record the selection process in sufficient detail to
complete a PRISMA flow diagram.
Data extraction and management
We will use the Cochrane EPOC (Effective Practice and
Organisation of Care) data collection form and adapt it
for our study characteristics. We will pilot the form and
adjust accordingly to suit the required study characteris-
tics. We will include studies reported in full. Abstracts
will be excluded if they do not have sufficient data. Two
reviewers [MU and MN] will independently extract the
following study characteristics from the selected studies:
study design, setting, and number of participants; inter-
vention characteristics (type of intervention, intensity of
the intervention, content of the intervention, and where
intervention was given); and comparison group and out-
comes (primary outcomes: glycated hemoglobin
(HBA1c), blood pressure control, and depression scores).
Risk of bias assessment
Two reviewers [MU and MN] will independently assess risk
of bias for each study using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interven-
tions [24]. Any disagreement will be resolved by discussion
or by involving a third reviewer [MM]. We will assess the
risk of bias according to the following domains: (1) random
sequence generation, (2) allocation concealment, (3) blind-
ing of participants and personnel, (4) blinding of outcome
assessment, (5) incomplete outcome data, (6) selective out-
come reporting, (7) baseline outcomes measurement, (8)
baseline characteristics, and (9) other bias. We will judge
each potential source of bias as high, low, or unclear and
provide a quote from the study report together with a justi-
fication for our judgment in the “risk of bias” table. We will
summarize the “risk of bias” judgements across different
studies for each of the domains listed. We will consider
blinding separately for different key outcomes where neces-
sary. Where information on risk of bias relates to unpub-
lished data, we will note this in the “risk of bias” table. We
will not exclude studies on the grounds of their risk of bias,
but will clearly report the risk of bias when presenting the
results of the studies. When considering treatment effects,
we will take into account the risk of bias for the studies that
contribute to that outcome. We will use the Grading of
Recommendations, Assessment, Development and Evalu-
ation (GRADE) criteria in assessing the overall quality of
evidence for specific quantitative outcomes.
Data synthesis
We will follow data synthesis methods proposed in the
PRISMA [25, 26] and Cochrane [24] publications. We will
report studies using descriptive statistics. We will do both
narrative synthesis and meta-analysis. In narrative synthe-
sis, we will do structured synthesis using descriptive statis-
tics and might use forest plot if necessary. A funnel plot
will also be used to explore publication bias. In order to
facilitate meta-analysis, prevalence data will be trans-
formed using appropriate statistical methods. We will
standardize data on the effects of depression management.
We will assess methodological and statistical heterogen-
eity using I2. We will use Stata v.14 in the absence of sta-
tistically significant heterogeneity to pool and analyze the
data using the random effects model in the event of mul-
tiple interventions or multiple outcomes. We will conduct
sensitivity analyses on study quality and patient-related
heterogeneity in order to explore the robustness of the re-
sults of the primary outcome.
Discussion
We will report the findings from this review according to
the PRISMA [25, 26]. The discussion will be drawn from
findings of the synthesis. Practice- and policy-relevant as-
pects of applicability will be addressed in this section. The
proposed systematic review will provide evidence which
will be used in guiding practice and policy on how to inte-
grate depression management in diabetes and hyperten-
sion care to improve patient outcomes.
Potential limitations of review methods
These review findings may have a bias introduced by
limiting the language to English-only articles published
since 1990. The review team does not have the capacity
to translate languages. The protocol will be revised to in-
clude studies published before 1990 if very few
post-1990 are identified.
Abbreviations
BP: Blood pressure; EPOC: Effective Practice and Organisation of Care;
FPG: Fasting plasma glucose; GRADE: Grading of Recommendations,
Assessment, Development and Evaluation; LMICs: Low- and middle-income
countries; NCDs: Non-communicable diseases; PRISMA-P: Preferred Reporting
Items of Systematic Reviews and Meta-Analyses Protocol
Acknowledgements
We acknowledge the African Mental Health Research Initiative (AMARI)
which has provided a fellowship to MU for his PhD. The systematic review
will form part of MU’s PhD work.
Funding
This systematic review protocol presents independent work supported
through the DELTAS Africa Initiative [DEL-15-01]. The DELTAS Africa Initiative
is an independent funding scheme of the African Academy of Sciences
(AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA) and
supported by the New Partnership for Africa’s Development Planning and
Coordinating Agency (NEPAD Agency) with funding from the Wellcome
Trust [DEL-15-01] and the UK government. The views expressed in this
Udedi et al. Systematic Reviews           (2018) 7:223 Page 4 of 5
publication are those of the author(s) and not necessarily those of AAS,
NEPAD Agency, Wellcome Trust, or the UK government.
Availability of data and materials
Not applicable
Authors’ contributions
MU was responsible for the protocol writing. MU, BP, FK, and AM were
involved in the conceptualization of the study. BP, FK, and AM edited the
protocol. MU and MN will be responsible for searching the literature and
data management. MU and MN will be responsible for the article screening,
data extraction, and quality assurance. All authors read and approved the
final manuscript.
Authors’ information
MU is an AMARI PhD fellow and is being supervised by AM, FK, and BP.





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1College of Medicine, University of Malawi, P/Bag 360, Chichiri, Blantyre 3,
Malawi. 2Department of Epidemiology, University of North Carolina-Chapel
Hill, McGavran-Greenberg, 2103C Campus Box 7435, UNC-Chapel Hill, Chapel
Hill, NC 27599-7435, USA.
Received: 16 June 2017 Accepted: 23 November 2018
References
1. Buttorff C, et al. Economic evaluation of a task-shifting intervention for common
mental disorders in India. Bull World Health Organ. 2012;90(11):813–21.
2. Mendenhall E, et al. Depression and type 2 diabetes in low- and middle-
income countries: a systematic review. Diabetes Res Clin Pract. 2014;103(2):
276–85.
3. Nikolic, I.A., A.E. Stanciole, and M. Zaydman, Chronic emergency: why NCDs
matter. Health, nutrition, and population discussion paper, 2011.
4. Bădescu SV, et al. The association between diabetes mellitus and
depression. J Med Life. 2016;9(2):120–5.
5. Association, A.P., Diagnostic and statistical manual of mental disorders
(DSM-5®). 2013: American Psychiatric Pub.
6. Li Z, et al. Prevalence of depression in patients with hypertension: a
systematic review and meta-analysis. Medicine. 2015;94(31):e1317.
7. Sartorius N. Depression and diabetes. Dialogues Clin Neurosci. 2018;20(1):
47–52.
8. Moussavi S, et al. Depression, chronic diseases, and decrements in health:
results from the World Health Surveys. Lancet. 2007;370(9590):851–8.
9. Kessler RC, Bromet EJ. The epidemiology of depression across cultures.
Annu Rev Public Health. 2013;34:119–38.
10. Voinov, B., W.D. Richie, and R.K. Bailey, Depression and chronic diseases: it is
time for a synergistic mental health and primary care approach. The Primary
Care Companion for CNS Disorders, 2013. 15(2): p. PCC.12r01468.
11. Semenkovich K, et al. Depression in type 2 diabetes mellitus: prevalence,
impact, and treatment. Drugs. 2015;75(6):577–87.
12. Ngo VK, et al. Grand challenges: integrating mental health care into the
non-communicable disease agenda. PLoS Med. 2013;10(5):e1001443.
13. Gehi A, et al. Depression and medication adherence in outpatients with
coronary heart disease: findings from the Heart and Soul Study. Arch Intern
Med. 2005;165(21):2508–13.
14. Rieckmann N, et al. Course of depressive symptoms and medication
adherence after acute coronary syndromes: an electronic medication
monitoring study. J Am Coll Cardiol. 2006;48(11):2218–22.
15. Mensah GA, Collins PY. Understanding mental health for the prevention
and control of cardiovascular diseases. Glob Heart. 2015;10(3):221–4.
16. Al-Amer RM, et al. Depression among adults with diabetes in Jordan: risk
factors and relationship to blood sugar control. J Diabetes Complicat. 2011;
25(4):247–52.
17. Akena D, et al. The association between depression, quality of life, and the
health care expenditure of patients with diabetes mellitus in Uganda. J
Affect Disord. 2015;174:7–12.
18. Aghili R, et al. Type 2 diabetes: model of factors associated with glycemic
control. Can J Diabetes. 2016;40(5):424–30.
19. Agbir TM, et al. Depression among medical outpatients with diabetes: a
cross-sectional study at Jos University Teaching Hospital, Jos, Nigeria. Ann
Afr Med. 2010;9(1):5–10.
20. Atlantis E, Fahey P, Foster J. Collaborative care for comorbid depression and
diabetes: a systematic review and meta-analysis. BMJ Open. 2014;4(4).
21. van der Feltz-Cornelis CM, et al. Effect of interventions for major depressive
disorder and significant depressive symptoms in patients with diabetes
mellitus: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2010;
32(4):380–95.
22. Ekers D, et al. Nurse-delivered collaborative care for depression and long-
term physical conditions: a systematic review and meta-analysis. J Affect
Disord. 2013;149(1–3):14–22.
23. National Collaborating Centre for Mental, H., National Institute for Health
and Clinical Excellence: Guidance, in Depression in adults with a chronic
physical health problem: treatment and management. 2010, The British
Psychological Society & The Royal College of Psychiatrists.: Leicester.
24. Higgins JP, Green S. Cochrane handbook for systematic reviews of
interventions, vol. 4. Chichester: Wiley; 2011.
25. Welch V, et al. PRISMA-equity 2012 extension: reporting guidelines for
systematic reviews with a focus on health equity. PLoS Med. 2012;9(10):
e1001333.
26. Moher D, et al. Preferred reporting items for systematic reviews and meta-
analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.
27. Moher D, et al. Preferred reporting items for systematic review and meta-
analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews. 2015;4(1):1.
28. Lustman PJ, Clouse RE. Depression in diabetic patients: the relationship
between mood and glycemic control. J Diabetes Complicat. 2005;19(2):113–22.
29. Bolívar JJ. Essential hypertension: an approach to its etiology and
neurogenic pathophysiology. Int J Hypertens. 2013;2013:11.
30. American Diabetes, A., Diagnosis and classification of diabetes mellitus.
Diabetes Care, 2010. 33(Suppl 1): p. S62-S69.
31. World Bank Country and Lending Groups. 2018 [cited 2018 4 August];
Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/
906519-world-bank-country-and-lending-groups.
Udedi et al. Systematic Reviews           (2018) 7:223 Page 5 of 5
